
    
      After screening (week -8), patients enter in a run-in period of 6 weeks during which
      treatment is unchanged. At week -2, if persistent proteinuria is confirmed (uP/C ratio â‰¥1
      expressed in mg/mg), patients will be randomized in a 1/1 ratio to 1 of 2 treatment groups as
      follows :

      RTX group Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.Control group
      Subjects will not receive RTX infusions. In both arms, azathioprine (AZA) or mycophenolate
      mofetil (MMF) will be continued. If prescribed, prednisolone dose should not be > 10 mg/day.
    
  